Science Daily: Pharmacology News

JULY 31, 2023

Applying this photoenzymatic approach, researchers have developed a clean, efficient way to synthesize crucial chemical building blocks known as chiral amines, solving a longstanding challenge in synthetic chemistry.

Synthetic Chemistry 157

Synthetic Chemistry Production Research 157

The Strateos Blog: Drug Discovery

AUGUST 16, 2021

Director of Chemistry of Strateos gave an interactive talk focused on how automated robotics and integrated software are powering self-driving labs that are revolutionizing synthetic chemistry to support medicinal chemistry workflows. Director of R&D Strategy and Vince Yeh, Ph.D.,

Synthetic Chemistry 52

Synthetic Chemistry Small Molecule Drugs Clinical Trials 52

The Strateos Blog: Drug Discovery

SEPTEMBER 24, 2021

On September 15th, Strateos hosted Part 2 of its Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis. Ben Miles, Ph.D., Head of Product Management at Strateos was joined by Josh Bond, Director of Product Management at PerkinElmer Informatics to discuss this exciting collaboration.

Synthetic Chemistry 52

Synthetic Chemistry Small Molecule Production Science 52

DrugBaron

FEBRUARY 7, 2022

A lot of resources are therefore poured into synthetic chemistry, and if the compound family is at all synthetically challenging it can require dozens, even hundreds, of chemists to churn out every imaginable variant.

Small Molecule 100

Small Molecule Synthetic Chemistry Pharma Companies Pharmacokinetics 100

Drug Target Review

JANUARY 19, 2024

At USP India, Dr Jaywant oversees the Compendial Development, the Synthetic Chemistry, and the Analytical Research and Development Laboratories. About the author Dr Mrunal Jaywant Vice President of R&D at USP India Dr Jaywant has been with USP for seven years and has more than 27 years of experience in the pharmaceutical industry.

Synthetic Chemistry 106

Synthetic Chemistry Analytical Chemistry Pharmaceuticals Pharma Companies 106

The Pharma Data

DECEMBER 2, 2020

Kazumi holds a PhD in Synthetic Chemistry from UC Berkeley. Kazumi started her career at AbbVie (then Abbott Labs) and from there joined Millennium (now part of Takeda), where she worked in senior functions in both research and corporate development. She is also a Board member of the Sandford Burnham Prebys Institute.

Pharmaceuticals 52

Pharmaceuticals Synthetic Chemistry RNA Disease 52

The Pharma Data

JANUARY 27, 2021

These include in-vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities.

FDA 52

FDA Synthetic Chemistry Assay Development Treatment 52